Novartis CEO Vas Narasimhan stated the company will not join the weight loss drug market, focusing instead on unique areas like treatments for secondary effects of weight loss. Avoiding direct competition with major obesity drugmakers, Narasimhan highlighted Novartis’ research in reducing side effects and retaining muscle mass. The company aims to target winning areas like Alzheimer’s, Huntington’s, Parkinson’s, and cancer therapies, particularly its radioligand therapies, expecting to build a $20 billion business and maintain a distinct position in the market.
Full Article
US Postal Service suspends China packages as tariff war heats up
The US Postal Service has temporarily suspended package delivery from China, impacting ecommerce groups like Temu and Shein due to new tariffs imposed by President Trump. Chinese logistics companies are now charging extra fees to cover the increased levies, affecting exporters and increasing costs for US consumers. The abrupt implementation of tariffs caught many by surprise, leading to uncertainty and chaos in the ecommerce industry as Chinese sellers navigate the changes and potentially raise prices...
Read more